Transplantation of purified pluripotent stem cell-derived cardiomyocytes into damaged myocardium might become a therapy to improve contractile function after myocardial infarction. However, engraftment remains problematic. Aim of this study was to investigate whether murine embryonic fibroblasts (MEFs) support the functional integration of purified embryonic stem cell-derived cardiomyocytes (ES-CMs). Neonatal murine ventricular tissue slices were subjected to oxygen and glucose deprivation to simulate irreversible ischemia. Vital tissue slices served as control. Vital and avital tissue slices were cultured with or without MEFs before coculturing with clusters of puromycin-selected ES-CMs. Integration of ES-CM clusters was assessed morphologically, motility by long-term microscopy, and functional integration by isometric force measurements. We observed a good morphological integration into vital but a poor integration into avital slices. Adding MEFs improved morphological integration into irreversibly damaged slices and enabled purified ES-CMs to migrate and to confer force. We conclude that noncardiomyocytes like MEFs support morphological integration and force transmission of purified ES-CMs by enabling adhesion and migration.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS, JonesJM. 1998. Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
6.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK, YamanakaS. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
IedaM, FuJD, Delgado-OlguinP, VedanthamV, HayashiY, BruneauBG, SrivastavaD. 2010. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 142:375–386.
9.
LaflammeMA, ZbindenS, EpsteinSE, MurryCE. 2007. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol, 2:307–339.
10.
van LaakeLW, PassierR, Monshouwer-KlootsJ, VerkleijAJ, LipsDJ, FreundC, den OudenK, Ward-van OostwaardD, KorvingJ, TertoolenLG, van EchteldCJ, DoevendansPA, MummeryCL. 2007. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res, 1:9–24.
11.
KolossovE, BostaniT, RoellW, BreitbachM, PillekampF, NygrenJM, SasseP, RubenchikO, FriesJW, WenzelD, GeisenC, XiaY, LuZ, DuanY, KettenhofenR, JovingeS, BlochW, BohlenH, WelzA, HeschelerJ, JacobsenSE, FleischmannBK. 2006. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med, 203:2315–2327.
ChienKR. 2006. Lost and found: cardiac stem cell therapy revisited. J Clin Invest, 116:1838–1840.
14.
EbeltH, JungblutM, ZhangY, KubinT, KostinS, TechnauA, OustaninaS, NiebruggeS, LehmannJ, WerdanK, BraunT. 2007. Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells, 25:236–244.
15.
GnecchiM, HeH, LiangOD, MeloLG, MorelloF, MuH, NoiseuxN, ZhangL, PrattRE, IngwallJS, DzauVJ. 2005. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med, 11:367–368.
KinnairdT, StabileE, BurnettMS, LeeCW, BarrS, FuchsS, EpsteinSE. 2004. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res, 94:678–685.
18.
PillekampF, HalbachM, ReppelM, RubenchykO, PfannkucheK, XiJY, BlochW, SreeramN, BrockmeierK, HeschelerJ. 2005. Neonatal murine heart slices. A robust model to study ventricular isometric contractions. Cell Physiol Biochem, 20:837–846.
19.
ZhangJG, GhoshS, OcklefordCD, GalinanesM. 2000. Characterization of an in vitro model for the study of the short and prolonged effects of myocardial ischaemia and reperfusion in man. Clin Sci (Lond), 99:443–453.
20.
PillekampF, ReppelM, RubenchykO, PfannkucheK, MatzkiesM, BlochW, SreeramN, BrockmeierK, HeschelerJ. 2007. Force measurements of human embryonic stem cell-derived cardiomyocytes in an in vitro transplantation model. Stem Cells, 25:174–180.
21.
PijnappelsDA, SchalijMJ, RamkisoensingAA, van TuynJ, de VriesAA, van der LaarseA, YpeyDL, AtsmaDE. 2008. Forced alignment of mesenchymal stem cells undergoing cardiomyogenic differentiation affects functional integration with cardiomyocyte cultures. Circ Res, 103:167–176.
22.
OttHC, MatthiesenTS, GohSK, BlackLD, KrenSM, NetoffTI, TaylorDA. 2008. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med, 14:213–221.
CamellitiP, BorgTK, KohlP. 2005. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res, 65:40–51.
25.
SanoM, FukudaK, KodamaH, PanJ, SaitoM, MatsuzakiJ, TakahashiT, MakinoS, KatoT, OgawaS. 2000. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem, 275:29717–29723.
26.
WeberKT, BrillaCG. 1991. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 83:1849–1865.
27.
PfannkucheK, NeussS, PillekampF, FrenzelL, AttiaW, HannesT, SalberJ, HossM, ZenkeM, FleischmannB, HeschelerJ, SaricT. 2010. Fibroblasts facilitate the engraftment of embryonic stem cell-derived cardiomyocytes on three-dimensional collagen matrices and aggregation in hanging drops. Stem Cells Dev, 19:1589–1599.
28.
GisselC, DossMX, Hippler-AltenburgR, HeschelerJ, SachinidisA. 2006. Generation and characterization of cardiomyocytes under serum-free conditions. Methods Mol Biol, 330:191–219.
29.
PillekampF, ReppelM, BrockmeierK, HeschelerJ. 2006. Impulse propagation in late-stage embryonic and neonatal murine ventricular slices. J Electrocardiol, 39:425.e1–e4.
30.
BanerjeeI, FuselerJW, PriceRL, BorgTK, BaudinoTA. 2007. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol, 293:H1883–H1891.
31.
WesselsA, Pérez-PomaresJM. 2004. The epicardium and epicardially derived cells (EPDCs) as cardiac stem cells. Anat Rec A Discov Mol Cell Evol Biol, 276:43–57.
NorrisRA, BorgTK, ButcherJT, BaudinoTA, BanerjeeI, MarkwaldRR. 2008. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann N Y Acad Sci, 1123:30–40.
34.
MännerJ, Pérez-PomaresJM, MacíasD, Muñoz-ChápuliR. 2001. The origin, formation and developmental significance of the epicardium: a review. Cells Tissues Organs, 169:89–103.
35.
Jane-LiseS, CordaS, ChassagneC, RappaportL. 2000. The ECM and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev, 5:239–250.
SniderP, StandleyKN, WangJ, AzharM, DoetschmanT, ConwaySJ. 2009. Origin of cardiac fibroblasts and the role of periostin. Circ Res, 105:934–947.
38.
DeschampsAM, SpinaleFG. 2005. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol, 20:211–216.
39.
IedaM, TsuchihashiT, IveyKN, RossRS, HongTT, ShawRM, SrivastavaD. 2009. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell, 16:233–244.
40.
La FramboiseWA, ScaliseD, StoodleyP, GranerSR, GuthrieRD, MagovernJA, BecichMJ. 2007. Cardiac fibroblasts influence cardiomyocytes phenotype in vitro. Am J Physiol Cell Physiol, 292:C1799–C1808.
41.
KohlP, CamellitiP, BurtonFL, SmithGL. 2005. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J Electrocardiol, 38,4 Suppl.:45–50.
42.
PorterKE, TurnerNA. 2009. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther, 123:255–278.
43.
AtanceJ, YostMJ, CarverW. 2004. Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J Cell Physiol, 200:377–386.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
